BillionToOne, Inc. (BLLN) Stock Analysis
Range Bound setup
Healthcare · Diagnostics & Research
Hold if already holding. Not a fresh buy at $83.38, but acceptable to hold if already in. Reasons: Concentration risk — Product: molecular diagnostic tests; Concentration risk — Counterparty: third-party payors (90.0%).
BillionToOne provides single-molecule next-generation sequencing (smNGS) diagnostic tests for prenatal genetic screening (UNITY suite) and oncology liquid biopsy (Northstar Select, Northstar Response). Revenue comes primarily from third-party payor reimbursement for its... Read more
Hold if already holding. Not a fresh buy at $83.38, but acceptable to hold if already in. Reasons: Concentration risk — Product: molecular diagnostic tests; Concentration risk — Counterparty: third-party payors (90.0%). Chart setup: RSI 56 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 5.6/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — BillionToOne, Inc.
Latest news
- BillionToOne (NASDAQ:BLLN) Momentum Fuels Nasdaq Healthcare Interest - Kalkine Media — Kalkine Media positive
- Solid Earnings Reflect BillionToOne's (NASDAQ:BLLN) Strength As A Business - Yahoo Finance — Yahoo Finance positive
- Guggenheim raises BillionToOne stock price target to $120 on reimbursement progress - Investing.com UK — Investing.com UK positive
- Guggenheim raises BillionToOne stock price target to $120 on reimbursement progress - Investing.com — Investing.com positive
- BillionToOne (BLLN) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance — Yahoo Finance neutral
Generated 2026-05-21T00:51:20Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductmolecular diagnostic tests10-K Item 1A: 'We primarily generate revenue from sales of our molecular diagnostic tests and we are highly dependent on them for our success'
- HIGHcounterpartythird-party payors90%10-K Item 1A: 'Reimbursement from third-party payors for our tests represented more than 90% of our revenue for each of the years ended December 31, 2025 and 2024'
Material Events(8-K, last 90d)
- 2026-03-04Item 5.02LOWBoard approved the BillionToOne Annual Incentive Plan effective January 1, 2026, to attract, retain, and motivate top performing employees. Compensatory arrangement only; no officer departures or appointments reported.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $83.38, but acceptable to hold if already in. Reasons: Concentration risk — Product: molecular diagnostic tests; Concentration risk — Counterparty: third-party payors (90.0%). Chart setup: RSI 56 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $102.41 (+22.8%), stop $77.54 (−7.5%), A.R:R 1.5:1. Score 5.6/10, moderate confidence.
Take-profit target: $102.41 (+22.8% upside). Target $102.41 (+22.8%), stop $77.54 (−7.5%), A.R:R 1.5:1. Stop-loss: $77.54.
Concentration risk — Product: molecular diagnostic tests; Concentration risk — Counterparty: third-party payors (90.0%); Expensive valuation.
BillionToOne, Inc. trades at a P/E of 152.4 (forward 79.9). TrendMatrix value score: 3.8/10. Verdict: Hold.
14 analysts cover BLLN with a consensus score of 4.2/5. Average price target: $118.
What does BillionToOne, Inc. do?BillionToOne provides single-molecule next-generation sequencing (smNGS) diagnostic tests for prenatal genetic...
BillionToOne provides single-molecule next-generation sequencing (smNGS) diagnostic tests for prenatal genetic screening (UNITY suite) and oncology liquid biopsy (Northstar Select, Northstar Response). Revenue comes primarily from third-party payor reimbursement for its molecular diagnostic tests, with >90% from third-party payors in both 2024 and 2025. The patented QCT platform enables single-DNA-molecule sensitivity, differentiating it from conventional NGS.